Respiratory Syncytial Virus Vaccine Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Respiratory Syncytial Virus Vaccine market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historic period can be attributed to the increasing burden of RSV, initiatives by governments and the WHO, rising healthcare awareness, and high hospitalization rates.

The projected growth in the forecast period is driven by the introduction of approved vaccines, global immunization programs, the expanding geriatric population, and the growth of healthcare infrastructure. Key trends in this period include technological advancements, the use of digital monitoring tools, the development of personalized vaccines, the creation of combination vaccines, and innovations in adjuvants.

The increasing prevalence of respiratory infections is expected to drive the growth of the respiratory syncytial virus (RSV) vaccine market. Respiratory infections are diseases caused by various pathogens, including viruses and bacteria, that affect the respiratory system, such as the sinuses, throat, airways, or lungs. Factors contributing to the rising incidence of these infections include air pollution, climate change, urbanization, an aging population, and the emergence of drug-resistant pathogens. The RSV vaccine helps reduce the incidence of infections by preventing RSV-related illnesses, particularly in vulnerable groups such as infants and the elderly. For example, the UK Health Security Agency reported in October 2024 that tuberculosis (TB) cases in England increased by 10.7% from 2022 to 2023, rising from 4,380 to 4,850 cases. This growing incidence of respiratory infections is expected to accelerate the RSV vaccine market's expansion.

A key trend in the RSV vaccine market is the increased focus on advancements in vaccine technology, particularly the use of recombinant protein-based technology. This technology involves the genetic engineering of proteins to create vaccines that stimulate an immune response. For example, in May 2023, GlaxoSmithKline plc, a UK-based pharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for Arexvy, the first RSV vaccine specifically designed to prevent lower respiratory tract disease caused by RSV in individuals aged 60 and older. Arexvy uses recombinant protein-based technology to target the RSV fusion (F) protein, which is critical to the virus's ability to infect human cells.

In February 2024, AstraZeneca PLC, a UK-based biopharmaceutical company, acquired Icosavax, Inc. for $1.1 billion. This acquisition strengthens AstraZeneca's pipeline of vaccines and immune therapies, with Icosavax's leading candidate, IVX-A12, targeting RSV and human metapneumovirus (hMPV), two key pathogens responsible for severe respiratory infections in high-risk groups such as the elderly and individuals with chronic conditions. Icosavax, a clinical-stage U.S.-based biopharmaceutical company, is actively developing an RSV vaccine with its lead candidate, IVX-A12.

Major companies operating in the respiratory syncytial virus vaccine market are Pfizer Inc., GlaxoSmithKline plc, and Moderna Inc.

North America was the largest region in the respiratory syncytial virus vaccine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in respiratory syncytial virus vaccine report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the respiratory syncytial virus vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

A respiratory syncytial virus (RSV) vaccine is a medical preparation aimed at protecting individuals, especially infants, older adults, and high-risk groups, from severe respiratory infections caused by RSV. It functions by stimulating the immune system to recognize and combat the virus, thus lowering the risk of hospitalization and severe illness.

The primary types of RSV vaccines include viral vaccines, bacterial vaccines, and combination vaccines. A viral vaccine is specifically designed to prevent infections caused by viruses. It covers various indications, including those for pediatric, geriatric, and high-risk populations, and is distributed through hospitals, pharmacies, and government suppliers.

The respiratory syncytial virus vaccines market research report is one of a series of new reports that provides respiratory syncytial virus vaccines market statistics, including respiratory syncytial virus vaccines industry global market size, regional shares, competitors with a respiratory syncytial virus vaccines market share, detailed respiratory syncytial virus vaccines market segments, market trends and opportunities, and any further data you may need to thrive in the respiratory syncytial virus vaccines industry. This respiratory syncytial virus vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The respiratory syncytial virus vaccine market consists of sales of protein-based vaccines, mRNA vaccines, monoclonal antibodies, and live-attenuated vaccines. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.